Skip to main content
main-content

Spondyloarthropathies

Medications

17-06-2019 | JAK inhibitors | EULAR 2019 | News

EQUATOR analysis shows patient-level response to filgotinib in PsA

Analysis of the EQUATOR trial has shown that patients treated with the Janus kinase inhibitor filgotinib for active psoriatic arthritis generally achieve a quick response that remains stable over time.

15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Expert commentary: The SPIRIT-H2H trial

Laura Coates discusses why the results of the SPIRIT-H2H trial are important for clinical practice (2:41).

15-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Researcher comment: The SPIRIT-H2H trial

Lead investigator Philip Mease discusses the findings from the SPIRIT-H2H trial, a phase III head-to-head trial of ixekizumab versus adalimumab in patients with psoriatic arthritis (7:15).

15-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Ixekizumab tops adalimumab in head-to-head PsA trial

Findings from the SPIRIT-H2H trial, presented at the EULAR 2019 congress in Madrid, Spain, have demonstrated superior efficacy of ixekizumab versus adalimumab among patients with psoriatic arthritis.

14-06-2019 | Axial spondyloarthritis | EULAR 2019 | News

BE AGILE: Bimekizumab shows promise for ankylosing spondylitis

Bimekizumab may offer a new therapeutic option for patients with ankylosing spondylitis, findings from the BE AGILE study indicate.

14-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Bimekizumab shows dual efficacy in patients with psoriatic arthritis

Research shows that patients with psoriatic arthritis gain substantial improvements in both musculoskeletal and skin symptoms with bimekizumab, highlighting the benefits of its ability to neutralize both interleukin-17A and 17F.

12-06-2019 | Psoriatic arthritis | EULAR 2019 | News

Tildrakizumab shows promise for PsA

Phase IIb trial results reported at the EULAR 2019 congress in Madrid, Spain, suggest that tildrakizumab may be a promising treatment option for people with psoriatic arthritis.

12-06-2019 | Psoriatic arthritis | EULAR 2019 | Article

Researcher comment: Tildrakizumab shows promise for PsA

Lead investigator Philip Mease outlines the results of a phase IIb trial supporting further development of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for the treatment of psoriatic arthritis (8:45).

10-06-2019 | Psoriatic arthritis | Feature | Article

A closer look at guidelines for the management of PsA

Laura Coates talks to medwireNews about the latest ACR/NPF guidelines for managing psoriatic arthritis, discussing the evidence supporting the recommendations and how they compare with others.

16-05-2019 | Psoriatic arthritis | News

Insights given into TNFi treatment patterns for patients with PsA

Patients initiating their first tumor necrosis factor inhibitor for psoriatic arthritis have a longer time to discontinuation and are less likely to switch treatment than those previously treated with a drug from the same class, say researchers.

15-05-2019 | Secukinumab | News

Pooled analysis demonstrates favorable long-term safety profile of secukinumab

Analysis of data from 21 randomized controlled trials indicates that the interleukin-17A inhibitor secukinumab has a favorable long-term safety profile among patients with psoriatic arthritis, ankylosing spondylitis, or psoriasis.

29-04-2019 | Etanercept biosimilar | News

FDA approves etanercept biosimilar

Click through for more information on this announcement

12-04-2019 | Ankylosing spondylitis | News

Infliximab withdrawal not recommended for AS patients in remission

The decision to discontinue infliximab in ankylosing spondylitis patients who have achieved sustained remission “should be taken with considerable caution,” say Spanish researchers who found that over half relapsed after the tumor necrosis factor inhibitor was withdrawn.

29-03-2019 | Axial spondyloarthritis | News

FDA approves certolizumab pegol for nonradiographic axSpA

Click through for more detail on this approval

Certolizumab pegol shows promise for nonradiographic axSpA

The tumor necrosis factor inhibitor certolizumab pegol could be an option for patients with active nonradiographic axial spondyloarthritis and objective signs of inflammation, indicate phase III trial results.

15-03-2019 | Axial spondyloarthritis | Highlight | News

Certolizumab pegol shows promise for nonradiographic axSpA

The tumor necrosis factor inhibitor certolizumab pegol could be an option for patients with active nonradiographic axial spondyloarthritis and objective signs of inflammation, indicate phase III trial results.

13-03-2019 | Axial spondyloarthritis | News

Adding conventional DMARDs to TNF inhibitors may be beneficial for obese axSpA patients

Using conventional synthetic DMARDs in addition to tumor necrosis factor inhibitor therapy may result in an increased likelihood of clinical response among overweight and obese patients with axial spondyloarthritis, researchers report.

Image Credits